+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the long-term safety, tolerability, and effectiveness of ML-007C-MA in adults with schizophrenia. This open-label Phase 2 study includes participants who have recently completed a previous related study or new participants enrolling directly. The study focuses on adults aged 18 to 65 diagnosed with schizophrenia who may benefit from ongoing pharmacotherapy and can maintain outpatient care. Participants will receive ML-007C-MA dosed at 2103 mg twice daily for up to 52 weeks. This single-group study does not involve placebo and assesses the medications impact over the treatment period. The study allows for continuous monitoring and adjustment based on the participants response and tolerability. During the study, participants will be involved in regular assessments to monitor safety and tolerability from the initial dose through the entire treatment period. Evaluations include clinical interviews, physical exams, ECGs, and laboratory tests to track any adverse effects or changes in health status. Researchers will also gather information from a reliable informant to support assessments. The total participation duration can be up to one year.

Age: 18Years - 65YearsAll GendersPhase 2
45 locations
P

Actively Recruiting

Researchers are evaluating zelquistinel, a drug aimed at reducing symptoms of major depressive disorder in adults aged 18 to 64 years. This Phase 2 clinical trial compares the effects and safety of zelquistinel to a placebo in participants diagnosed with major depressive disorder. The study will focus on changes in depression severity and monitor any medical issues that arise during treatment. Participants will take one tablet of either zelquistinel or placebo once a week for six weeks. The trial includes a screening period of up to 28 days, followed by a 42-day treatment phase, and then a four-week follow-up period. During treatment, participants will visit the clinic weekly to receive their dose and have their depression symptoms assessed using the Hamilton Depression Rating Scale-17. Throughout the study, participants will have their depression severity regularly evaluated, along with monitoring for adverse events or side effects. The study lasts up to 98 days, including screening, treatment, and follow-up. Researchers will measure changes in depression scores from the beginning to the end of treatment and monitor overall safety during this time.

Age: 18Years - 64YearsAll GendersPhase 2
32 locations
R

Actively Recruiting

Researchers are evaluating how well different doses of esketamine nasal spray work compared to a placebo in adults with treatment-resistant depression. This study focuses on individuals with major depressive disorder who have not improved after trying at least two different antidepressant treatments during their current depressive episode. The trial is designed to better understand the efficacy, safety, and tolerability of esketamine when used alone. Participants will be randomly assigned to receive either 56 mg or 84 mg of esketamine nasal spray, or a placebo, twice a week for four weeks in a double-blind phase. Those who finish this phase may join an open-label phase, where they can receive either 56 mg or 84 mg of esketamine for up to 12 weeks. The medication is self-administered as a nasal spray. During the study, participants will have regular evaluations measuring changes in depression symptoms using the Montgomery-Asberg Depression Rating Scale MADRS and other assessment tools. Researchers will monitor symptom changes from baseline through the double-blind and open-label phases. Safety and tolerability will also be tracked throughout the study, which is expected to continue until 2029.

Age: 18Years +All GendersPhase 3
39 locations
R

Actively Recruiting

This research aims to evaluate the feasibility, safety, and tolerability of aticaprant as an additional treatment for adults with schizophrenia. The study focuses on stable participants receiving outpatient care and on a stable antipsychotic medication dose. It compares aticaprant with a placebo to understand how well participants can complete the study and assessments. Participants are randomly assigned to receive either aticaprant or a placebo during the double-blind treatment phase. The study includes monitoring for adverse events, vital signs, ECG, laboratory parameters, body weight, BMI changes, suicidality, and extrapyramidal symptoms. The treatment and observation period lasts up to 126 days with various assessment points. During the study, participants will undergo regular evaluations including safety checks, symptom assessments, and blood tests. Researchers will track completion rates of assessments and study milestones. Safety monitoring covers changes in vital signs, ECG, lab results, and mental health symptoms. The total participation time can be up to approximately four months.

Age: 18Years - 60YearsAll GendersPhase 1
8 locations
E

Actively Recruiting

Researchers are evaluating the use of Vedolizumab in adults with moderate to severely active Ulcerative Colitis UC or Crohns Disease CD. These long-term gut conditions cause symptoms like diarrhea, inflammation, bleeding, and belly pain. The study aims to determine how many participants achieve remission, meaning their symptoms disappear, after 14 weeks of treatment. This is a Phase 4 treatment study sponsored by Takeda. Participants will receive Vedolizumab through two methods. For the first 6 weeks, they get 300 mg intravenously at weeks 0 and 2, with a possible additional dose at week 6. Afterward, starting by week 6 and definitely by week 14, the administration switches to 108 mg injections under the skin every 2 weeks until week 50. Participants who do not respond to treatment by week 14 will stop Vedolizumab and may switch to other treatments, with additional clinic visits at 26 and 52 weeks. A follow-up occurs 18 weeks after the last Vedolizumab dose. Throughout the study, participants have several clinic visits for treatments and assessments. Researchers will measure remission rates using patient-reported outcomes at weeks 6, 14, and 52, alongside clinical response, endoscopic results, and markers like C-reactive protein and fecal calprotectin. Safety is monitored by tracking serious infections up to 72 weeks. The total participation time spans about one year of treatment plus follow-up after treatment ends.

Age: 18Years - 80YearsAll GendersPhase 4
101 locations
R

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of SPT-300 GlyphAllo, a prodrug of allopregnanolone, in adults aged 18 to 65 years with major depressive disorder MDD, including those with or without anxious distress. This Phase 2 randomized, double-blind, placebo-controlled study aims to better understand how SPT-300 impacts depressive symptoms compared to placebo. Participants will be randomly assigned to receive either SPT-300 capsules or a matching placebo once daily for 42 days. The study is designed as a parallel-group trial with two arms one receiving the experimental drug SPT-300 and the other receiving placebo. Treatment effects will be closely monitored during this 6-week period. Throughout the study, participants will undergo assessments including the Hamilton Depression Rating Scale-17 HAM-D-17 and the Clinical Global Impression - Severity CGI-S to measure changes in depressive symptoms from baseline to day 42. Safety and tolerability will also be evaluated. The total participation duration extends until study completion in March 2027, with regular visits to monitor progress and well-being.

Age: 18Years - 65YearsAll GendersPhase 2
61 locations
R

Actively Recruiting

Researchers are studying adults with treatment-resistant depression TRD to evaluate the effects of ALTO-207 compared with a placebo. This clinical trial aims to measure changes in depressive symptoms, particularly focusing on the Montgomery-sberg Depression Rating Scale MADRS scores over eight weeks. The study is randomized, double-blind, and placebo-controlled, conducted by Alto Neuroscience. Participants receive either ALTO-207 or a matching placebo twice daily BID during the treatment phase. The trial follows a parallel design, comparing the effects of the experimental drug to placebo over the course of the study. Throughout the trial, participants undergo assessments including changes in MADRS scores and clinician-administered Clinical Global Impression-Severity CGI-S scores. The primary outcome is the change from baseline in MADRS total score up to eight weeks. Secondary outcomes include response rates and CGI-S score changes. Safety and adherence are monitored, with a total participation period extending through the eight-week treatment phase and follow-up.

Age: 18Years - 75YearsAll GendersPhase 2
63 locations
P

Actively Recruiting

Researchers are evaluating the drug NBI-1117568 in adults with schizophrenia to determine if it can delay the return of symptoms after a stable response to treatment. This Phase 3, placebo-controlled study focuses on adults between 18 and 65 years old who have already shown improvement with antipsychotic therapy. The trial is designed to assess the safety and effectiveness of NBI-1117568 in preventing relapse. Participants first enter an open-label stabilization period during which all receive NBI-1117568. Following this, they are randomly assigned to continue receiving either NBI-1117568 or a placebo in a double-blind treatment period. Both NBI-1117568 and placebo are given as oral capsules. The study includes a parallel design comparing these two groups. Throughout the study, participants will be closely monitored for relapse of schizophrenia symptoms over approximately 30 weeks. Researchers will measure the time from randomization to relapse as the primary outcome. Safety and tolerability are also assessed during the trial. The total study duration extends until July 2029, with regular evaluations to understand how well participants maintain symptom control.

Age: 18Years - 65YearsAll GendersPhase 3
25 locations
L

Actively Recruiting

Researchers are studying the long-term safety and tolerability of the drug NBI-1065845 when used alongside other treatments for adults with Major Depressive Disorder MDD. This Phase 3 trial focuses on participants who have moderate to severe recurrent MDD or persistent depressive disorder, particularly those who have not responded well to oral antidepressants in their current depressive episode. Participants will take NBI-1065845 tablets orally once a day as an additional treatment. The study is open-label and single group, meaning all participants receive the same treatment. The trial will observe participants over the course of one year while they take the medication. During the study, participants will undergo assessments to monitor any treatment-emergent adverse events from the start through week 52. Researchers will evaluate how well participants tolerate the medication and ensure their safety throughout the treatment period. The total participation duration corresponds to the one-year treatment and monitoring phase.

Age: 18Years +All GendersPhase 3
120 locations
S

Actively Recruiting

Researchers are studying the effects of NBI-1065845 compared with a placebo as an additional treatment for adults with Major Depressive Disorder MDD. This trial focuses on improving symptoms of depression in participants who have not responded well to standard oral antidepressant treatments during their current episode. The study is designed as a randomized, double-blind, placebo-controlled trial primarily evaluating treatment outcomes in this population. Participants will receive either NBI-1065845 tablets or placebo tablets that look identical. Both treatments are taken orally once a day alongside their current oral antidepressants, which participants must continue at the same dose and frequency throughout the study. The main treatment period lasts 56 days, during which researchers will monitor changes in depression symptoms and disability. Throughout the study, participants will undergo assessments including the Montgomery-sberg Depression Rating Scale MADRS, Sheehan Disability Scale SDS, and Clinical Global Impression-Severity Scale CGI-S at the start and end of the 56-day period. Researchers will evaluate changes in these scores to measure symptom improvement. The trial includes close monitoring to ensure participant safety and adherence, with total participation lasting about two months.

Age: 18Years +All GendersPhase 3
35 locations

1-10 of 12

1